Details for Patent: 8,680,144

Title:	Methods of treating mixed dyslipidemia
Abstract:	The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Inventor(s):	Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Filing Date:	May 20, 2013
Application Number:	13/898,457
Claims:	1. A method of treating hypertriglyceridemia in a subject in need thereof comprising, administering to the subject daily a statin and about 4 g of ethyl eicosapentaenoate effective to reduce fasting triglycerides and LDL-C relative to subjects having hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 2. The method of claim 1 wherein said administering step reduces fasting triglycerides by at least 10% relative to subjects with hypertriglyceridemia who are are receiving a statin without said ethyl eicosapentaenoate. 3. The method of claim 1 wherein said administering step reduces fasting triglycerides by at least 15% relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 4. The method of claim 1 wherein said administering step reduces fasting triglycerides by at least 20% relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 5. The method of claim 1 wherein said administering step reduces fasting triglycerides by at least 25% and LDL-C by at least 5% relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 6. The method of claim 1 wherein said administering step reduces fasting apolipoprotein B relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 7. The method of claim 1 wherein said administering step reduces fasting apolipoprotein B by at least 5% relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 8. The method of claim 1 wherein said administering step reduces fasting VLDL-C relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 9. The method of claim 1 wherein said administering step reduces fasting VLDL-C by at least 15% relative to subjects with hypertriglyceridemia who are receiving a statin without said ethyl eicosapentaenoate. 10. The method of claim 1 wherein the statin is selected from lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin and simvastatin. 11. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in 1 to about 10 dosage units per day. 12. The method of claim 11 wherein the dosage units comprise capsules. 13. The method of claim 1 wherein the ethyl eicosapentaenoate is administered to the subject in 1 to about 4 dosage units per day. 14. The method of claim 13 wherein the dosage units comprise capsules.